Funding for this research was provided by:
National Health and Medical Research Council (APP1030123)
Bayer HealthCare (N/A)
University of Adelaide (N/A)
University of Sydney (N/A)
Eli Lilly (N/A)
Received: 30 October 2018
Accepted: 30 May 2019
First Online: 19 June 2019
Ethics approval and consent to participate
: The following Human Review Ethics Committees approved the study’s recruitment strategies and also, where applicable, reviewed and approved promotional material: Sydney Local Health District HREC – CRGH, Central Adelaide Local Health Network Human Research Ethics Committee, South Metropolitan Health Service Human Research Ethics Committee, Bellberry Human Research Ethics Committee.
: Not applicable.
: GW has received research funding from Bayer, Lilly, Lawley Pharmaceuticals and Weight Watchers®, and speaker honoraria from Bayer, Lilly and Besins Healthcare.CA has received honoraria from Besins Healthcare and is an advisory board member for Ferring.MG has received research funding from Bayer, Novartis, Weight Watchers®, Lilly, and speaker’s honoraria from Besins Healthcare and Otsuka.DJH has received institutional grants for investigator-initiated studies of testosterone pharmacology (Lawley, Besins Healthcare) but no personal income and has provided expert testimony to anti-doping and professional standards tribunals and testosterone litigation.BBY has received speaker honoraria and conference support from Bayer, Lilly and Besins Healthcare, research support from Bayer, Lilly and Lawley Pharmaceuticals, and has been a member of advisory committees for Lilly and Besins Healthcare.All other authors declare no relevant conflicts of interest.